The Wegovy pill is the fastest-adopted GLP-1 in history. Orforglipron will let patients take a GLP-1 with breakfast. And Goldman Sachs projects oral GLP-1s will capture $22 billion in market share by 2030.
For years, the GLP-1 revolution came with a caveat: you had to self-inject. Weekly shots of semaglutide or tirzepatide delivered extraordinary weight loss — 15–22% of body weight — but needle aversion kept millions of eligible patients on the sidelines. That barrier fell on December 22, 2025, when the FDA approved the first oral GLP-1 for weight loss.
The response has been explosive. Within 10 weeks of launch, roughly 400,000 Americans were taking the Wegovy pill — outpacing the adoption rate of every prior GLP-1 introduction. And the oral market is about to get more competitive: Eli Lilly's orforglipron, which doesn't require fasting and can be taken at any time of day, is expected to receive FDA approval by mid-2026.
The oral Wegovy contains the same active ingredient as injectable Wegovy and Ozempic — semaglutide — reformulated with salcaprozate sodium (SNAC), an absorption enhancer that protects the peptide from stomach acid and enables absorption through the stomach lining.
The OASIS 4 trial showed the pill is clinically comparable to the injection. Using intent-to-treat analysis (which includes all participants regardless of adherence), mean weight loss was 13.6% at approximately 64 weeks. Among patients who stayed on treatment, it was 16.6%, with one-third achieving 20% or greater body weight loss. These numbers are comparable to injectable Wegovy's 15–17% in the STEP trials.
The pill has strict dosing requirements that patients must follow for it to work properly:
Dosing starts at 1.5 mg and gradually titrates up to the maintenance dose of 25 mg, with increases every 4 weeks based on tolerability.
Through NovoCare, the self-pay price starts at $149/month for the 1.5 mg starting dose, with higher doses up to $299/month. This makes it the most affordable GLP-1 entry point from a brand-name manufacturer. TrumpRx.gov lists GLP-1 pills starting at $149.
Explore both oral and injectable GLP-1 programs. Licensed providers help match you to the right format based on your needs, preferences, and budget.
Explore Options →If the Wegovy pill solved the needle problem, orforglipron solves the convenience problem. Eli Lilly's oral GLP-1 can be taken at any time of day, with or without food, and without the 30-minute fasting window. For patients who take morning medications, drink coffee first thing, or simply find the fasting requirement difficult to maintain, this is a significant practical advantage.
The reason: orforglipron is a small-molecule drug, not a peptide. While semaglutide (Wegovy pill) is a modified version of the injectable peptide that needs special formulation to survive stomach acid, orforglipron was designed from the ground up as an oral compound. It doesn't need SNAC or any absorption-enhancing technology.
Phase 3 results show weight loss of 7.5–11.2% at 72 weeks in patients without diabetes (ATTAIN-1). This is lower than injectable semaglutide or tirzepatide, but the convenience tradeoff may be worth it for many patients. In diabetes trials (ACHIEVE-3), orforglipron showed comparable glucose control to oral semaglutide. The ATTAIN-MAINTAIN study demonstrated successful weight maintenance when patients switched from injectable GLP-1s to orforglipron — average regain was just 0.9 kg when transitioning from Wegovy.
Eli Lilly expects FDA approval by mid-2026. Self-pay pricing through LillyDirect will start at $149 for the lowest dose, up to $399 for higher doses. At $50/month for Medicare beneficiaries upon approval, orforglipron could become the most widely prescribed oral GLP-1.
| Feature | Wegovy Pill | Orforglipron |
|---|---|---|
| Status | FDA-approved (Dec 2025) | FDA decision expected mid-2026 |
| Weight Loss | ~15% (adherent patients) | 7.5–11.2% |
| Dosing | Daily, empty stomach, AM | Daily, any time, with/without food |
| Fasting Required | Yes — 30 min before eating | No |
| Self-Pay Price | $149–299/mo | $149–399/mo (expected) |
| Drug Class | Peptide GLP-1 | Small molecule GLP-1 |
| Maker | Novo Nordisk | Eli Lilly |
Clinicians interviewed by multiple outlets have indicated that orforglipron will become their preferred oral GLP-1 once approved — specifically because of the no-fasting convenience. The Wegovy pill's 30-minute empty-stomach requirement is a practical barrier that affects adherence, especially for patients who take morning medications like thyroid drugs, blood pressure pills, or proton pump inhibitors.
Amycretin (Novo Nordisk): An oral dual GLP-1/amylin agonist currently in Phase 3. If successful, it would be the first oral drug targeting two weight-loss hormones simultaneously — potentially achieving efficacy closer to injectable levels.
Market projections: Goldman Sachs estimates oral GLP-1s will capture 24% of the anti-obesity drug market ($22 billion) by 2030. With approximately 39 GLP-1 medications currently in development, the oral segment is where much of the innovation is focused.
For patients currently on injectable semaglutide or tirzepatide who are happy with their results, there's no clinical reason to switch to a pill — the injectable forms deliver higher weight loss. But for patients who:
...the oral options offer a viable and increasingly well-supported alternative. The ATTAIN-MAINTAIN data showing successful weight maintenance after switching from injectables to oral GLP-1 is particularly reassuring for patients considering this transition.
Licensed providers to help you evaluate whether oral or injectable GLP-1 therapy best fits your lifestyle. Transparent pricing.
Explore Options →